Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpha Tau Medical Ltd. - Warrant (NQ:DRTSW)

0.2504 +0.0106 (+4.42%)
Streaming Delayed Price Updated: 1:52 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,907
Open 0.2286
Bid (Size) 0.2504 (2)
Ask (Size) 0.2505 (26)
Prev. Close 0.2398
Today's Range 0.2286 - 0.2505
52wk Range 0.0883 - 0.5000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ... 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
From Alpha Tau Medical Ltd.
Via GlobeNewswire

Performance

YTD
+4.3%
+4.3%
1 Month
+10.3%
+10.3%
3 Month
+1.8%
+1.8%
6 Month
+6.6%
+6.6%
1 Year
+4.3%
+4.3%

More News

Read More
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Treats First Patient with Recurrent Lung Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau to Present at Upcoming November Investor Conferences
From Alpha Tau Medical Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Warrant publicly traded?
Yes, Alpha Tau Medical Ltd. - Warrant is publicly traded.
What exchange does Alpha Tau Medical Ltd. - Warrant trade on?
Alpha Tau Medical Ltd. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Alpha Tau Medical Ltd. - Warrant?
The ticker symbol for Alpha Tau Medical Ltd. - Warrant is DRTSW on the Nasdaq Stock Market
What is the current price of Alpha Tau Medical Ltd. - Warrant?
The current price of Alpha Tau Medical Ltd. - Warrant is 0.2504
When was Alpha Tau Medical Ltd. - Warrant last traded?
The last trade of Alpha Tau Medical Ltd. - Warrant was at 06/09/25 01:52 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.